GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Ruxolitinib tablets (JAKAFI)

Local RX List renal extractBase record retrieved 2026-09-07See the evidence for this drug1 sources available - open source summaries, references and comparisons

JAKAFI

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
CrCl alone does not select the JAKAFI starting regimen

The renal starting-dose table changes by indication and, for myelofibrosis, platelet count. The dialysis rows also use indication-specific post-dialysis schedules.

Before applying: Establish indication and platelet category before reading a dose. This selected table is not the full cytopenia, interaction or toxicity-management algorithm.

Also check: CrCl alone does not select the JAKAFI starting regimen

Rxlist source

GlobalRPh RX List - JAKAFI

Product / population
Oral ruxolitinib: adult myelofibrosis/polycythemia vera and indication-specific GVHD starting regimens; confirm the labeled age and hematologic eligibility. Not topical ruxolitinib.
Renal measure
Creatinine clearance, mL/min; platelet count x 10^9/L.

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Renal dosing, restrictions and evidence limits

For CrCl 15-59 mL/min, starting doses depend on indication. Myelofibrosis: platelets above 150 x 10^9/L, no renal change; 100-150, 10 mg twice daily; 50 to below 100, 5 mg daily; below 50, avoid. Polycythemia vera: 5 mg twice daily. Acute GVHD: 5 mg daily. Chronic GVHD: 5 mg twice daily. For ESRD on dialysis, give only after dialysis: myelofibrosis with platelets 100-200, 15 mg once; above 200, 20 mg once; polycythemia vera, 10 mg once; acute GVHD, 5 mg once; chronic GVHD, 10 mg once. The table does not supply a myelofibrosis dialysis starting dose below platelets 100. Avoid when CrCl is below 15 without dialysis. These are starting schedules, not subsequent cytopenia, interaction or response adjustments.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/jakafi-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

GlobalRPh RX List

GlobalRPh RX List - JAKAFI

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Oral ruxolitinib: adult myelofibrosis/polycythemia vera and indication-specific GVHD starting regimens; confirm the labeled age and hematologic eligibility. Not topical ruxolitinib.

Renal method: Creatinine clearance, mL/min; platelet count x 10^9/L.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

indication and blood count

CrCl alone does not select the JAKAFI starting regimen

The renal starting-dose table changes by indication and, for myelofibrosis, platelet count. The dialysis rows also use indication-specific post-dialysis schedules.

How to use this: Establish indication and platelet category before reading a dose. This selected table is not the full cytopenia, interaction or toxicity-management algorithm.

GlobalRPh RX List - JAKAFI

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGlobalRPh RX List - JAKAFI
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/jakafi-drug/

Exact product and population

Oral ruxolitinib: adult myelofibrosis/polycythemia vera and indication-specific GVHD starting regimens; confirm the labeled age and hematologic eligibility. Not topical ruxolitinib.

RDM36-SCOPE-ruxolitinib-jakafi · Source section: Selected source product scopeRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - JAKAFI

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Oral ruxolitinib: adult myelofibrosis/polycythemia vera and indication-specific GVHD starting regimens; confirm the labeled age and hematologic eligibility. Not topical ruxolitinib.

Renal method: Creatinine clearance, mL/min; platelet count x 10^9/L.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For CrCl 15-59 mL/min, starting doses depend on indication. Myelofibrosis: platelets above 150 x 10^9/L, no renal change; 100-150, 10 mg twice daily; 50 to below 100, 5 mg daily; below 50, avoid. Polycythemia vera: 5 mg twice daily. Acute GVHD: 5 mg daily. Chronic GVHD: 5 mg twice daily. For ESRD on dialysis, give only after dialysis: myelofibrosis with platelets 100-200, 15 mg once; above 200, 20 mg once; polycythemia vera, 10 mg once; acute GVHD, 5 mg once; chronic GVHD, 10 mg once. The table does not supply a myelofibrosis dialysis starting dose below platelets 100. Avoid when CrCl is below 15 without dialysis. These are starting schedules, not subsequent cytopenia, interaction or response adjustments.

RDM36-rxlist-ruxolitinib-jakafi-0b9891c8ed-C1 · Source locator: Dosage: Table 10, Dose Modifications for Renal Impairment.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/jakafi-drug/
Retrieved
2026-09-07
Renal-function method
Creatinine clearance, mL/min; platelet count x 10^9/L.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
53ebfdc2eea1b9b5dde405acf53c9c944aed5b66d631862413d50d0d1963a06e

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/jakafi-drug/
Source retrieval
2026-09-07. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
755d5c1f2860c5d39028f4fcc1bf4aa046825f4d2a2c5451643a9f8c3174135e
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report